BACKGROUND: In high-income countries, depression is prevalent in HIV patients and is associated with lower medication adherence and clinical outcomes. Emerging evidence from low-income countries supports similar relationships. Yet little research has validated rapid depression screening tools integrated into routine HIV clinical care. METHODS: Using qualitative methods, we adapted the Patient Health Questionnaire-9 (PHQ-9) depression screening instrument for use with Cameroonian patients. We then conducted a cross-sectional validity study comparing an interviewer-administered PHQ-9 to the reference standard Composite International Diagnostic Interview in 400 patients on antiretroviral therapy attending a regional HIV treatment center in Bamenda, Cameroon. RESULTS: The prevalence of major depressive disorder (MDD) in the past month was 3% (n=11 cases). Using a standard cutoff score of ≥10 as a positive depression screen, the PHQ-9 had estimated sensitivity of 27% (95% confidence interval: 6-61%) and specificity of 94% (91-96%), corresponding to positive and negative likelihood ratios of 4.5 and 0.8. There was little evidence of variation in specificity by gender, number of HIV symptoms, or result of a dementia screen. LIMITATIONS: The low prevalence of MDD yielded very imprecise sensitivity estimates. Although the PHQ-9 was developed as a self-administered tool, we assessed an interviewer-administered version due to the literacy level of the target population. CONCLUSION: The PHQ-9 demonstrated high specificity but apparently low sensitivity for detecting MDD in this sample of HIV patients in Cameroon. Formative work to define the performance of proven screening tools in new settings remains important as research on mental health expands in low-income countries.
BACKGROUND: In high-income countries, depression is prevalent in HIVpatients and is associated with lower medication adherence and clinical outcomes. Emerging evidence from low-income countries supports similar relationships. Yet little research has validated rapid depression screening tools integrated into routine HIV clinical care. METHODS: Using qualitative methods, we adapted the Patient Health Questionnaire-9 (PHQ-9) depression screening instrument for use with Cameroonian patients. We then conducted a cross-sectional validity study comparing an interviewer-administered PHQ-9 to the reference standard Composite International Diagnostic Interview in 400 patients on antiretroviral therapy attending a regional HIV treatment center in Bamenda, Cameroon. RESULTS: The prevalence of major depressive disorder (MDD) in the past month was 3% (n=11 cases). Using a standard cutoff score of ≥10 as a positive depression screen, the PHQ-9 had estimated sensitivity of 27% (95% confidence interval: 6-61%) and specificity of 94% (91-96%), corresponding to positive and negative likelihood ratios of 4.5 and 0.8. There was little evidence of variation in specificity by gender, number of HIV symptoms, or result of a dementia screen. LIMITATIONS: The low prevalence of MDD yielded very imprecise sensitivity estimates. Although the PHQ-9 was developed as a self-administered tool, we assessed an interviewer-administered version due to the literacy level of the target population. CONCLUSION: The PHQ-9 demonstrated high specificity but apparently low sensitivity for detecting MDD in this sample of HIVpatients in Cameroon. Formative work to define the performance of proven screening tools in new settings remains important as research on mental health expands in low-income countries.
Authors: Bruce Arroll; Felicity Goodyear-Smith; Susan Crengle; Jane Gunn; Ngaire Kerse; Tana Fishman; Karen Falloon; Simon Hatcher Journal: Ann Fam Med Date: 2010 Jul-Aug Impact factor: 5.166
Authors: Alfred K Njamnshi; Vincent de Paul Djientcheu; Julius Y Fonsah; Faustin N Yepnjio; Dora M Njamnshi; Walinjom E Muna Journal: J Acquir Immune Defic Syndr Date: 2008-12-01 Impact factor: 3.731
Authors: Abiodun O Adewuya; Mohammed O Afolabi; Bola A Ola; Olorunfemi A Ogundele; Adeola O Ajibare; Bamidele F Oladipo; Ibiyemi Fakande Journal: Int J Psychiatry Med Date: 2008 Impact factor: 1.210
Authors: Patrick O Monahan; Enbal Shacham; Michael Reece; Kurt Kroenke; Willis Owino Ong'or; Otieno Omollo; Violet Naanyu Yebei; Claris Ojwang Journal: J Gen Intern Med Date: 2008-11-20 Impact factor: 5.128
Authors: Rebecca B Hershow; H Luz McNaughton Reyes; Tran Viet Ha; Geetanjali Chander; Nguyen Vu Tuyet Mai; Teerada Sripaipan; Constantine Frangakis; David W Dowdy; Carl Latkin; Heidi E Hutton; Audrey Pettifor; Suzanne Maman; Vivian F Go Journal: Drug Alcohol Depend Date: 2020-06-10 Impact factor: 4.492
Authors: Kathryn E Lancaster; Vivian F Go; Thandie Lungu; Pearson Mmodzi; Mina C Hosseinipour; Katy Chadwick; Kimberly A Powers; Brian W Pence; Irving F Hoffman; William C Miller Journal: Int J Drug Policy Date: 2016-02-26
Authors: Mariame Sylla; Andre C Vogel; Aissatou K Bah; Nana R Tassiou; Souleymane D Barry; Bachir A Djibo; Mohamed L Toure; Sakadi Foksona; Mamady Konaté; Fode A Cisse; Farrah J Mateen Journal: Epilepsy Behav Date: 2020-11-11 Impact factor: 2.937
Authors: Sarah A MacLean; Kathryn E Lancaster; Thandie Lungu; Pearson Mmodzi; Mina C Hosseinipour; Brian W Pence; Bradley N Gaynes; Irving F Hoffman; William C Miller Journal: Int J Ment Health Addict Date: 2017-11-14 Impact factor: 3.836
Authors: Brian W Pence; Bradley N Gaynes; Julius Atashili; Julie K O'Donnell; Dmitry Kats; Kathryn Whetten; Alfred K Njamnshi; Tabenyang Mbu; Charles Kefie; Shantal Asanji; Peter Ndumbe Journal: AIDS Behav Date: 2014-06
Authors: Kathryn E Lancaster; Thandie Lungu; Pearson Mmodzi; Mina C Hosseinipour; Katy Chadwick; Kimberly A Powers; Brian W Pence; Vivian F Go; Irving F Hoffman; William C Miller Journal: AIDS Care Date: 2016-07-21